Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Cure H, Battista C, Guastalla JP et al. (2004) hase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC Study. Proceedings ASCO 23: 449
2. Fenelly D, Schneider J, Spriggs D et al. (1995) Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of avanced ovarian cancer patients receuving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13: 1160–1166
3. Goncalves A, Delva R, Fabrro M et al. (2006) Post-operative sequential high-dose chemotheapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. Bone Marrow Transplant 37: 651–659
4. Ledermann JA, Frickhofen N, Wandt H et al. (2005) A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. J Clin Oncol [Suppl]: 23: 5006
5. Legros M, Dauplat J, Fleury J et al. (1997) High-dose chemotherapy with hematopoetic rescue in patients with stage III to IV ovarian cancer : Long term results. J Clin Oncol 15: 1302–1308